Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

UNNT: A novel Utility for comparing Neural Net and Tree-based models

Impact of Molecular Representations on Deep Learning Model Comparisons in Drug Response Predictions

A Novel Approach For Drug Response Prediction In Cancer Cell Lines Via Network Representation Learning

Screen efficiency comparisons of decision tree and neural network algorithms in machine learning assisted drug design

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Performance Comparisons of AlexNet and GoogLeNet in Cell Growth Inhibition IC50 Prediction

Understanding the Sources of Performance in Deep Drug Response Models Reveals Insights and Improvements

Deep-learning: investigating deep neural networks hyper-parameters and comparison of performance to shallow methods for modeling bioactivity data

BioXNet: a biologically inspired neural network for deciphering anti-cancer drug response in precision medicine

Precision Anti-Cancer Drug Selection via Neural Ranking

Performance assessment of variant UNet-based deep-learning dose engines for MR-Linac-based prostate IMRT plans

Evaluating deep neural networks in optimizing drug discovery and precision medicine: A review

NeuMF: Predicting Anti-cancer Drug Response Through a Neural Matrix Factorization Model

A comprehensive benchmarking of machine learning algorithms and dimensionality reduction methods for drug sensitivity prediction

Deep learning methods for drug response prediction in cancer: Predominant and emerging trends

Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery

Assessing Reusability of Deep Learning-Based Monotherapy Drug Response Prediction Models Trained with Omics Data

Learning Curves for Drug Response Prediction in Cancer Cell Lines

DBDNMF: A Dual Branch Deep Neural Matrix Factorization method for drug response prediction

Validating the validation: reanalyzing a large-scale comparison of deep learning and machine learning models for bioactivity prediction